262 related articles for article (PubMed ID: 37382961)
1. Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Macdougall IC; Ponikowski P; Stack AG; Wheeler DC; Anker SD; Butler J; Filippatos G; Göhring UM; Kirwan BA; Kumpeson V; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1124-1134. PubMed ID: 37382961
[TBL] [Abstract][Full Text] [Related]
2. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
[TBL] [Abstract][Full Text] [Related]
3. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
Rosano G; Ponikowski P; Vitale C; Anker SD; Butler J; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Metra M; Ruschitzka F; Kumpeson V; Goehring UM; van der Meer P; Jankowska EA;
Cardiovasc Diabetol; 2023 Aug; 22(1):215. PubMed ID: 37592272
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
6. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF;
N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463
[TBL] [Abstract][Full Text] [Related]
7. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
8. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
Metra M; Jankowska EA; Pagnesi M; Anker SD; Butler J; Dorigotti F; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Rosano G; Ruschitzka F; Tomasoni D; van der Meer P; Ponikowski P;
Eur J Heart Fail; 2022 Oct; 24(10):1928-1939. PubMed ID: 35869741
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
Ponikowski P; Mentz RJ; Hernandez AF; Butler J; Khan MS; van Veldhuisen DJ; Roubert B; Blackman N; Friede T; Jankowska EA; Anker SD
Eur Heart J; 2023 Dec; 44(48):5077-5091. PubMed ID: 37632415
[TBL] [Abstract][Full Text] [Related]
10. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
McEwan P; Ponikowski P; Davis JA; Rosano G; Coats AJS; Dorigotti F; O'Sullivan D; Ramirez de Arellano A; Jankowska EA
Eur J Heart Fail; 2021 Oct; 23(10):1687-1697. PubMed ID: 34191394
[TBL] [Abstract][Full Text] [Related]
12. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
[TBL] [Abstract][Full Text] [Related]
13. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
McEwan P; Harrison C; Binnie R; Lewis RD; Cohen-Solal A; Lund LH; Ohlsson M; von Haehling S; Comin-Colet J; Pascual-Figal DA; Wächter S; Dorigotti F; de Arellano AR; Ponikowski P; Jankowska EA
Eur J Heart Fail; 2023 Mar; 25(3):389-398. PubMed ID: 36718652
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study.
McEwan P; Ponikowski P; Shiri T; Rosano GMC; Coats AJS; Dorigotti F; Ramirez de Arellano A; Jankowska EA
J Med Econ; 2023; 26(1):51-60. PubMed ID: 36476095
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
Caravita S; Faini A; Vignati C; Pelucchi S; Salvioni E; Cattadori G; Baratto C; Torlasco C; Contini M; Villani A; Malfatto G; Perger E; Lombardi C; Piperno A; Agostoni P; Parati G
Eur J Heart Fail; 2022 Oct; 24(10):1940-1949. PubMed ID: 35867685
[TBL] [Abstract][Full Text] [Related]
16. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR; Cleland JGF; Petrie MC; Thomson EA; Kalra PA; Squire IB; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Foley PWX; Graham FJ; Japp AG; Lane RE; Lang NN; Ludman AJ; Macdougall IC; Pellicori P; Ray R; Robertson M; Seed A; Ford I;
Lancet; 2022 Dec; 400(10369):2199-2209. PubMed ID: 36347265
[TBL] [Abstract][Full Text] [Related]
17. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
[TBL] [Abstract][Full Text] [Related]
19. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
